华蟾素胶囊联合肝动脉灌注化疗栓塞治疗肝癌患者的疗效

[目的]探究华蟾素胶囊联合肝动脉灌注化疗栓塞术(TACE)治疗肝癌患者的应用效果.[方法]于本院接受治疗的肝癌患者68例.随机分为A组和B组,各34例.A组在TACE的基础上联合服用华蟾素胶囊,B组仅行肝动脉TACE.比较两组治疗前后血浆纤维蛋白原(FIB)含量、肿瘤标志物浓度变化及其临床疗效、生活质量.[结果]治疗前两组FIB含量相比较差异无显著性(P＞0.05).A组治疗前后FIB含量相比较差异无显著性(P＞0.05),B组治疗后FIB含量明显高于治疗前,且明显高于A组(均P＜0.05).两组治疗后细胞角蛋白19片段、CEA、NSE浓度均明显低于治疗前,且差异有显著性(P＜0.05);但A组此三项指标治疗后与B组比较差异无显著性(P＞0.05).A组患者疾病控制率为77.5％ (26/34)明显高于B组67.6％(23/34),A组疼痛、疲倦发生率明显低于B组(P＜0.05).[结论]华蟾素胶囊联合TACE能够改善患者血液的高凝状态,有利于提升患者疾病控制率,改善患者生活.

Effect of Huachansu (Cinobufacini)Capsule Combined with Hepatic Arterial Infusion Chemoembolization in Patients with Liver Cancer

[Objective] To investigate the effect of cinobufacini capsules combined with hepatic arterial infusion chemoembolization in patients with liver cancer.[Methods]Sixty-eight patients with hepatocellular carcinoma treated in our hospital were randomly divided into group A and group B,34 cases in each.On the basis of TACE,the Group A was treated with the cinobufacini capsules,and the Group B underwent hepatic artery TACE only.The changes of plasma fibrinogen (FIB),tumor markers,clinical efficacy and quality of life were compared between the two groups before and after treatment.[Results] There was no significant difference in FIB content between the two groups before treatment (P ＞0.05),and no significant difference existed in FIB content in the Group A before and after treatment (P ＞0.05);The FIB content in the group B was significantly higher than that before treatment,and was even significantly higher than that in the Group A (mean P ＜0.05).After treatment,the Cy tokeratin 19 fragments,CEA,NSE concentrations of the two groups were significantly lower than those before treatment,and the difference was significant (P ＜0.05).It showed no significant difference between the three indexes of the Group A and the Group B after treatment (P ＞0.05).The disease control rate of the Group A was 77.5％ (26/34),which was significantly higher than that of the Group B 67.6％ (23/34);The incidence of pain and fatigue in the Group A was significantly lower than that in the Group B (P ＜0.05).[Conclusion]Cinobufacini capsules combined with TACE can improve the hypercoagulable state of blood in patients,which is beneficial for the treatment of cancer,improve the control rate of disease and improve the life quality of patients.